BIOT Stock News & Catalysts – Instinct Bio Technical Co.

FEATURED

INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives

NEW YORK and TOKYO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ:BIOT) ("Instinct Bio" or the "Company") today provided an operational update on the

Summary

Sep 4, 2026, 7:00 AM ·Globe Newswire

RECENT

Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia

NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ:BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT PARVA

Aug 10, 2026, 7:00 AM ·Globe Newswire

BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets

NEW YORK and TOKYO, July 29, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ:BIOT) ("Instinct Bio" or the "Company") today announced its decision to bring its own Japanese

Jul 29, 2026, 10:28 AM ·Globe Newswire

Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Makes Its Nasdaq Debut Under the Ticker “BIOT” on July 24, 2026

New York, NY, Las Vegas, NV, Tokyo, JP, July 23, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. ("Instinct Bio," "BIOT," or the "Company"), the parent company of Instinct

Jul 23, 2026, 4:15 PM ·Globe Newswire

Biotech Acquisition Company Announces Liquidation

New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete

Feb 1, 2023, 7:50 PM ·Globe Newswire

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed

Jan 4, 2023, 5:51 PM ·PRNewswire

Blade Therapeutics to Participate in "Drug Development in Pulmonary Medicine" Panel Discussion at 2022 BTIG Biotechnology Conference

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and

Aug 1, 2022, 8:00 AM ·Business Wire

Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global

Jun 13, 2022, 8:06 AM ·PRNewswire

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

Extraordinary General Meeting of BAC's shareholders postponed until a to-be-determined later dateNEW YORK and SOUTH SAN FRANCISCO, Calif., June 2, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT)

Jun 2, 2022, 8:58 PM ·PRNewswire

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

Extraordinary General Meeting of BAC's shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern TimeNEW YORK and SOUTH SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT)

May 31, 2022, 7:30 AM ·PRNewswire

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

NEW YORK, May 24, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it

May 24, 2022, 9:13 AM ·PRNewswire

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

Cudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model Non-competitive autotaxin inhibition by cudetaxestat maintained potency in the presence of elevated

May 18, 2022, 9:01 AM ·Business Wire

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

No significant drug-drug interaction (DDI) seen with cudetaxestat in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF) Cudetaxestat was well tolerated

May 16, 2022, 9:01 AM ·Business Wire

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity Facility

Extraordinary General Meeting of BAC's shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern TimePost-closing company will be renamed "Blade Biotherapeutics, Inc." upon Business Combination

May 9, 2022, 6:10 PM ·PRNewswire

Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

NEW YORK, April 4, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it

Apr 4, 2022, 3:49 PM ·PRNewswire

Instinct Bio Technical Co. Holdings Inc. BIOT · News